Pacific Bridge NY is a venture fund that partners with leading biotech innovators to advance high-potential therapeutics through U.S.-centric clinical development and company building.
EMPOWERING GLOBAL PARTNERSHIPS
At Pacific Bridge NY, we specialize in fostering collaboration. The fund invests in companies and programs with strong biological rationale and clear paths to approval in Western markets. By combining proprietary sourcing in other countries with hands-on clinical and operational support in the U.S., we seek to turn under-resourced scientific assets into globally competitive therapeutics.
Unlocking Global
Potential
We work closely with company leadership teams to analyze promising programs and position them for commercial success. Our team brings strategic guidance, development expertise, and business development support to our portfolio companies. We are committed to building a framework where innovation can move freely, talent can collaborate across geographies, and scientific breakthroughs gain the momentum they need to improve patient outcomes worldwide.
KEY PILLARS
To bridge global innovation with U.S. company creation, our model combines cross-border opportunity sourcing, deep clinical expertise, and adaptable company-building structures. These pillars guide how we identify high-potential assets, partner with world-class teams, and build ventures designed for efficient development and meaningful value creation.
Cross-Border Focus
Clinical & Regulator Expertise
Flexible Company-Building Model
Aligned with Structural Tailwinds
Strong interest in opportunities where global intellectual property can be licensed or partnered or international preclinical or clinical expertise can be brought to bear.
Supported by an experienced Clinical Advisory Board and consulting network that inform indication selection, trial design, and global development strategies for our portfolio companies.
Structures NewCos, joint ventures, PIPEs and other creative structures to potentially enhance value for Pacific Bridge NY, our limited partners, and our portfolio companies.
Shifts in manufacturing, global funding, and policies create both opportunities and challenges in biotech. Our cross-border model is built with flexibility to be able to support opportunities across geographies.